Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium 99Tc methylene diphosphonate
- Development stage
- Preclinical
- Lead developer
- Chengdu Yunke Pharmaceutical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Technetium 99Tc methylene diphosphonate is a radiopharmaceutical developed by Chengdu Yunke Pharmaceutical Co., Ltd. It functions as an anti-inflammatory and anti-bone destruction agent. Its mechanism of action involves inhibiting macrophage infiltration and downregulating proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). Additionally, it exhibits anti-osteoclastogenic activity, promotes osteoblast proliferation, and influences the OPG/RANKL/RANK system by increasing osteoprotegerin (OPG) expression and decreasing receptor activator of nuclear factor kappa-B ligand (RANKL) expression. It also binds to hydroxyapatite crystals in bone. Primarily used in China, it has been marketed for the treatment of rheumatoid arthritis and osteoporosis.
- Brand names
- Yunke
- Other names
- medronate
02
Targets
OPG (Osteoprotegerin)TNFRSF11A (RANK)TNFA (Tumor necrosis factor alpha (soluble))RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on technetium 99Tc methylene diphosphonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium 99Tc methylene diphosphonate.